Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIO-SWITCH: Switching to ferric citrate hydrate for iron deficiency anemia with prior oral iron intolerance
jRCTs031210634Completed
- Sponsor
- Torii Pharmaceutical
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of norethindrone + ethinyl estradiol in iron deficiency anemia (IDA), sponsored by Torii Pharmaceutical. Primary endpoint: Completion rate of medication during the study period. Started Apr 2022; status: completed.
02
Drugs
norethindrone + ethinyl estradiol
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on jRCTs031210634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210634.